Facility Spotlight: Winnipeg, Manitoba, Canada

For more than 30 years, our Winnipeg, Manitoba (Canada) site has offered a broad range of expertise for drug substance and drug product manufacturing. The 150,000-sq.ft. facility manufactures polyclonal hyperimmune products, plasma therapeutics, lipoproteins, and mRNA products, and houses a SA25 aseptic filling workcell — a gloveless, robotic isolator ideal for high-value biologic products.


Learn more about how our Winnipeg site is equipped to support your next clinical or commercial drug candidate.

Outsourced Pharma Capacity Update | July 2023

Kevin Yarnall, Sr. Manager, Manufacturing, presented Emergent's manufacturing capabilities and available capacity at its...

READ MORE

4 Steps for a Smooth Tech Transfer When Working with a CDMO

In our recent article with BioPharma Dive, Emergent's Shelly Buhay, Director of MS&T and Dan Perrin, Director of Manufacturing...

READ MORE

Webinar: Finding Solutions for public health threats: COVID-19

What are innovators doing to speed up the path to treating and preventing COVID-19?

The novel coronavirus has quickly taken...

READ MORE